Some evidence suggests that CD4+ T cells are more amenable to lentiviral transduction than CD8+ T cells, whereas modification via CRISPR/Cas-mediated knock-in leads to equal editing of both CD4+ and CD8+ T cells, resulting in higher CD8+/CD4+ ratios, which is important for tumor control [13]. The gene discussed is CD4; the disease is neoplasm.